Author:
Grey-Davies Elisabeth,Bosworth Jennifer L.,Boyd Kevin D.,Ebdon Caroline,Saso Radovan,Chitnavis Dipti,Mercieca Jane E.,Morgan Gareth J.,Davies Faith E.
Reference9 articles.
1. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Bladé;British Journal of Haematology,1998
2. Bendamustine: a new look at an old drug;Kalaycio;Cancer,2009
3. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy;Knop;Haematologica,2005
4. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents;Leoni;Clinical Cancer Research,2008
5. Bendamustine in patients with relapsed or refractory multiple myeloma;Michael;European Journal of Medical Research,2010
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献